A Phase I, Open-Label, Dose Escalation Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors.
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2014
At a glance
- Drugs Eritoran (Primary)
- Indications Leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Eisai Medical Research
- 03 Dec 2008 New trial record.